Hypermutated colorectal cancer with POLE/POLD1 variants may benefit from therapy with immune checkpoint inhibitors (ICIs) [12], providing new treatment opportunities for patients carrying POLE/POLD1 variants. Here, POLD1 is linked to colorectal cancer.